A veteran biotech CEO argues that true accomplishment lies in assembling and empowering great teams, not claiming personal credit for milestones like drug approvals. He asserts that any leader who needs personal credit for collective achievements cannot be truly effective.

A CEO's primary role differs fundamentally based on company type. In an asset-centric biotech, the CEO must act as a hands-on program manager, micromanaging execution. In a platform company, the CEO must be deeply embedded in the science to predict and leverage the technology's long-term trajectory.

The core job of a Product Manager is not writing specs or talking to press; it's a leadership role. Success means getting a product to market that wins. This requires influencing engineering, marketing, and sales without any formal authority, making it the ultimate training ground for real leadership.

The transition from a leadership role at a large pharma company like Gilead to a biotech CEO involves a massive shift in scope. Instead of managing one large function with a large team, a biotech CEO is hands-on with every aspect of the company, from science to finance.

Investors don't look for a specific personality type in biotech founders. Instead, they use pattern recognition to identify a crucial trait: executional excellence. The ability to expertly manage the diverse functions of a biotech company—from clinical to CMC to regulatory—is paramount, and prior experience is the best indicator of this skill.

In a highly technical field, a leader's job is not to be the smartest person in the room. Instead, their role is to surround themselves with brilliant specialists, ask the right questions to connect disparate pieces of information, and guide the collective expertise toward a single, unified goal.

Kevin Pojasek credits his effectiveness to a deliberate 12-year journey through diverse roles—investing, company creation, research, and clinical operations. This broad experience allows a leader to understand how all parts of the company, from high-level strategy to detailed science, fit together.

Early-stage biotechs prioritize scientists to build the core platform. However, once a lead clinical program is identified, the critical hire becomes a Chief Medical Officer who can design the clinical strategy. This hire is timed to the program's maturation, not the company's age, reflecting a pivotal strategic shift.

The CEO's role isn't to be the primary innovator but to enable a high-performing team. This "basketball coach" model focuses on providing the resources, culture, and strategic direction for the experts on the team to succeed, rather than trying to score all the baskets personally.